Horton, C., LaDuca, H., Blanco, K., Lo, M., Speare, V., Dolinsky, J., Kurian, A. Previously, Mr. Kurian went toIndian Institute of Technology Madras where he studied for six months. These new findings suggest a need to re-evaluate the use of risk-reducing medication to avoid invasive breast cancer and breast cancer death in high-risk women.We adapted an established Cancer Intervention and Surveillance Modeling Network model to evaluate the lifetime benefits and harms of risk-reducing medication in women with a 3% 5-year risk of developing breast cancer according to the Breast Cancer Surveillance Consortium risk calculator. B., Zhou, R., Kozlov, A., DeMartini, W., Chen, S., Okamoto, S., Ikeda, D. M., Mattonen, S. A., Napel, S., Alkim, E., Sledge, G. W., Kurian, A. W., Liu, M., Telli, M. L., Itakura, H. Harnessing artificial intelligence to automate delineation of volumetric breast cancers from magnetic resonance imaging to improve tumor characterization. Eight genes (ATM, BARD1, BRCA1, BRCA2, CHEK2, PALB2, PTEN, and TP53) were associated with breast cancer, with odds ratios (ORs) ranging from two-fold (ATM: OR, 1.74; 95% CI, 1.46 to 2.07) to six-fold (BRCA1: OR, 5.91; 95% CI, 5.25 to 6.67). She is also a clinically active oncologist, treating patients diagnosed with breast cancer. Clinicians should collect toxicity data routinely and offer early intervention. We conducted a survey of cancer genetic counselors based in the United States through the National Society of Genetic Counselors to assess the impact of reimbursement and patient OOP share on ordering of an HCP and hereditary cancer genetic counseling. When treatment was randomly assigned among women ages 18-75 years with RS 26-30, the mean DRFS hazard ratio for endocrine vs chemoendocrine therapy was 1.60 (0.83). A., Lipson, J. Investigations into potential targets of iniparib and its Choi, Y. H., Terry, M. B., Daly, M. B., MacInnis, R. J., Hopper, J. L., Colonna, S. n., Buys, S. S., Andrulis, I. L., John, E. M., Kurian, A. W., Briollais, L. n. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Hall, M. J., Hughes, E., Handorf, E., Gutin, A., Allen, B., Hartman, A., Kurian, A. W. Association of ovarian cancer (OC) risk with mutations detected by multiple-gene germline sequencing in 95,561 women. Ghanouni, P., Kurian, A. W., Margolis, D., Hartman, A., Mills, M. A., Plevritis, S. K., Ford, J. M., Daniel, B. L. BRCA1/2 mutations and cancer risk in Asian-Americans, Kurian, A. W., Chun, N. M., Mills, M. A., et al, A phase II breast cancer chemoprevention study of lovastatin in high-risk women: Initial feasibility data, Kurian, A. W., Sharma, V. B., Schwartz, E. J., et al, The role of BRCA1 in DNA repair and chemosensitivity. She is also a clinically active oncologist, treating patients diagnosed with breast cancer. Parikh, D. A., Dickerson, J. C., Kurian, A. W. Combined associations of a polygenic risk score and classical risk factors with breast cancer risk. John, E. M., Koo, J., Ingles, S. A., Kurian, A. W., Hines, L. M. Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry. Regression models examined factors associated with chemotherapy recommendations and receipt by the RS and subgroups.There were 1527 patients with stage I/II, estrogen receptor/progesterone receptor-positive, human epidermal growth factor 2-negative disease: 778 received an RS (62.6% of patients with node-negative, favorable disease, 24.3% of patients with node-negative, unfavorable disease, and 13.0% of patients with node-positive disease; P, View details for Web of Science ID 000394719100007. During the follow-up period, 9% of patients (95% CI, 3% to 19%) developed second cancers, and in 14% of patients (95% CI, 7% to 26%), a first-degree relative developed cancer, some of which were detected by recommended screening.Patients with a pathogenic variant in a less familiar cancer susceptibility gene report high adherence to risk-reducing interventions. However, studies seem to suggest that statins may be protective and are not likely to be harmful in the setting of cancer, suggesting that cancer patients who already take statins should not have this medication discontinued. Linking routine electronic health record (EHR) data with clinical registry data allows one to gain a more complete picture of the patient journey through a cancer care episode. View details for DOI 10.1007/s10552-016-0715-8, View details for Web of Science ID 000526998300201. Among 1569 patients (65.5%) without high genetic risk or an identified mutation, 598 (39.3%) reported a surgeon recommendation against CPM, of whom only 12 (1.9%) underwent CPM, but among the 746 (46.8%) of these women who received no recommendation for or against CPM from a surgeon, 148 (19.0%) underwent CPM.Many patients consider CPM, but knowledge about the procedure is low and discussions with surgeons appear to be incomplete. It was validated on manually annotated data from 224 patients with recurrence and achieved 0.94 AUROC. These may be useful in the patient's decision-making process and impact uptake of risk-management options. Multivariable logistic regression models accounting for family history were used to examine the association between pathogenic mutations and breast or ovarian cancer. View details for DOI 10.1158/1055-9965.EPI-22-1128, Low-frequency variants play an important role in breast cancer (BC) susceptibility. Studies of TNBC patients in the current era have revealed associations of TNBC with mutations in several moderate penetrance breast cancer susceptibility genes, including PALB2, BARD1, BRIP1, RAD51C and RAD51D. Unique associations include an inverse relation of serous cancer risk to body mass index, a positive relation of mucinous cancer risk to cigarette smoking, and a weakly positive relation of endometrioid cancer risk to body mass index. Projected Reductions in Absolute Cancer-Related Deaths from Diagnosing Cancers Before Metastasis, 2006-2015. Larger studies are needed to identify risk factors and prognostic significance associated with atypia and non-fluid-yielding ducts in high-risk populations, and define their role as biomarkers. Mr. Kurians other twin George speaks of his mother for being both loving and strict. We examined risk factors for SPLC across multiple epidemiologic cohorts and assessed the impact of smoking cessation on reducing SPLC risk.We analyzed data from 7,059 participants in the Multiethnic Cohort (MEC) diagnosed with an initial primary lung cancer (IPLC) between 1993 and 2017. Sixty percent (n=187) reported feeling very or extremely concerned that the pandemic would affect their cancer and disproportionately experienced among those with advanced cancer stages compared with earlier stages (P<0.001). B., Eliassen, A. H., Eriksson, M., Evans, D. G., Fasching, P. A., Flyger, H., Fritschi, L., Gago-Dominguez, M., Garca-Senz, J. In this study, we developed a weak-supervision framework for breast cancer recurrence prediction in which we trained a deep learning model on a large sample of free-text clinic notes by utilizing a combination of manually curated labels and NLP-generated non-perfect recurrence labels. We identified 6,004 women diagnosed with Stage I-III breast cancer at KPNC during 2004-2007; 2,669 (44.5 %) received at least one chemotherapy infusion at KPNC within 12 months of diagnosis. In previous reports, polygenic risk modification was reduced for BRCA1 and BRCA2 PV carriers compared with noncarriers, but limited information is available for carriers of CHEK2, ATM, or PALB2 PVs.To examine an 86-SNV polygenic risk score (PRS) for BRCA1, BRCA2, CHEK2, ATM, and PALB2 PV carriers.A retrospective case-control study using data on 150 962 women tested with a multigene hereditary cancer panel between July 19, 2016, and January 11, 2019, was conducted in a commercial testing laboratory. [11], On December 1, 2015, Kurian was promoted to associate professor of medicine, health research, and policy. View details for DOI 10.3390/cancers14112716. In this review, we summarize the current understanding of pathogenic germline gene mutations associated with TNBC and the early detection and prevention strategies for women at risk of developing this high-risk breast cancer subtype. Kurian, A. W., Kingham, K. E., Ford, J. M. How can we best respect patient autonomy in breast cancer treatment decisions? Compared with women whose test results were negative, those with BRCA1/2 pathogenic variants were more likely to receive bilateral mastectomy for a unilateral tumor (61.7% vs 24.3%; OR, 5.52, 95% CI, 4.73-6.44), less likely to receive postlumpectomy radiotherapy (50.2% vs 81.5%; OR, 0.22, 95% CI, 0.15-0.32), and more likely to receive chemotherapy for early-stage, ER/PR-positive disease (38.0% vs 30.3%; OR, 1.76 (95% CI, 1.31-2.34). Thomas Kurian, chief executive officer of Google Cloud, at the company's campus in Sunnyvale, California (Bloomberg) Thomas Kurian's changes have given momentum to Google Cloud and prompted. [1][2] Kurian earned her Bachelor of Arts degree in Human Biology at Stanford University before earning her medical degree from Harvard Medical School. O'Mara, A., Kurian, A., Benedict, C., Diver, E. Constitutional BRCA1 Methylation and Risk of Incident Triple-Negative Breast Cancer and High-grade Serous Ovarian Cancer. These patients had BRCA1 1479delAG, 3374insGA and W1712X mutations, respectively, with loss of heterozygosity at these loci in the pre-treatment tumors. Both types of overestimation were significantly associated with frequent worry, and lower QoL.Ensuring understanding of systemic recurrence risk, particularly among patients with favorable prognosis, is important. I have a strong focus on genetic risk assessment and precision oncology. We assessed the probability of these associations being true positives via the Bayesian false discovery probability (BFDP, View details for DOI 10.1186/s13058-021-01450-7. Participants completed questionnaires to measure quality of life (FACT-G), functional social support (Duke-UNC FSSQ), distress (PHQ-4), decision regret (DRS), and SM use.In total, 75.8% of the sample reported using SM. We used simulation modeling to fill these gaps.We simulated women eligible for TAILORx using joint distributions of patient and tumor characteristics and RS from TAILORx data; treatment effects by RS from other trials; and competing mortality from the Surveillance, Epidemiology, and End Results program database. A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer. Banerjee, I. n., Bozkurt, S. n., Caswell-Jin, J. L., Kurian, A. W., Rubin, D. L. Patient-clinician interactions and disparities in breast cancer care: the equality in breast cancer care study. Allison, K. H., Jensen, K., West, R., Clarke, C. A., Gomez, S. L., Kurian, A. W. Beyond Barriers: Systemic Constraints Limiting Sexual Health Care for Breast Cancer Survivors. Oakley-Girvan, I., Davis, S. W., Kurian, A., Rosas, L. G., Daniels, J., Palesh, O. G., Mesia, R. J., Kamal, A. H., Longmire, M., Divi, V. Widening cancer care disparities in the adoption of telemedicine during COVID 19: who is left behind? Extended aromatase inhibitor therapy in women 50-79had small absolute benefits and gains were offset by adverse events (loss of 0.06 discounted QALYs). Low-frequency variants were aggregated for individual genes' coding and regulatory regions. View details for DOI 10.1038/s41598-021-99409-3, Given the high heterogeneity among breast tumors, associations between common germline genetic variants and survival that may exist within specific subgroups could go undetected in an unstratified set of breast cancer patients.We performed genome-wide association analyses within 15 subgroups of breast cancer patients based on prognostic factors, including hormone receptors, tumor grade, age, and type of systemic treatment. Ghataorhe, P., Kurian, A. W., Pickart, A., Trapane, P., Norton, J. Among adopters, 52% initiated coverage pre-NCD over a 25-month period and 48% post-NCD over 17 months.We found an increase, but continued variability, in coverage over 3.5 years. Kurian, A. W., Sigal, B. M., Plevritis, S. K. Second Primary Breast Cancer Occurrence According to Hormone Receptor Status. A., Ham, C. M., Van Dam, J., Jeffrey, R. B., Longacre, T. A., Huntsman, D. G., Chun, N., Kurian, A. W., Ford, J. M. Ductal pattern enhancement on magnetic resonance imaging of the breast due to ductal lavage. Hey Im Tyson Corey Silva do I know you. Participants were followed for on average 11.45 years and there were 416 incident breast cancers. These results will guide a larger study of the tool's impact on clinical decisions. The histologic types of epithelial ovarian cancer differ in clinical behavior, descriptive epidemiology, and genetic origins. Confirmatory controlled trials are warranted. Prevalence and penetrance of breast cancer-associated mutations identified by multiple-gene sequencing in the Women's Health Initiative. Kim, S. M., Hatami, F., Harris, J. S., Kurian, A. W., Ford, J., King, D., Scalari, G., Giovannini, M., Hoyler, N., Faist, J., Harris, G. Comparative Analysis of Bio-Medical Imaging at 3.7 Terahertz with a High Power Quantum Cascade Laser, Kim, S. M., Hatami, F., Gu, A., Kurian, A. W., et al, A clinic-based study of BRCA1/2 mutation epidemiology in Asians, Kurian, A. W., Chun, N. M., Millls, M. A., et al, Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: an initial evaluation from a screening trial including magnetic resonance imaging and ductal lavage. We sought to assess the impact of primary language on health care engagement as indicated by clinical trial screening and engagement, use of genetic counseling, and communication via an electronic patient portal.Clinical and demographic data on patients with breast cancer diagnosed and treated from 2013 to 2018 within the Stanford University Health Care system were compiled via linkage of electronic health records, an internal clinical trial database, and the California Cancer Registry. Gomez, S., Yao, S., Kushi, L. H., Kurian, A. W. Simulation Modeling to Extend Clinical Trials of Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Early Breast Cancer. A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer. A., Gaudet, M. M., Giles, G. G., Goldberg, M. S., Goldgar, D. E., Gunel, P. n., Haiman, C. A., Hkansson, N. n., Hall, P. n., Harrington, P. A., Hart, S. N., Hartman, M. n., Hillemanns, P. n., Hopper, J. L., Hou, M. F., Hunter, D. J., Huo, D. n., Ito, H. n., Iwasaki, M. n., Jakimovska, M. n., Jakubowska, A. n., John, E. M., Kaaks, R. n., Kang, D. n., Keeman, R. n., Khusnutdinova, E. n., Kim, S. W., Kraft, P. n., Kristensen, V. N., Kurian, A. W., Le Marchand, L. n., Li, J. n., Lindblom, A. n., Lophatananon, A. n., Luben, R. N., Lubiski, J. n., Mannermaa, A. n., Manoochehri, M. n., Manoukian, S. n., Margolin, S. n., Mariapun, S. n., Matsuo, K. n., Maurer, T. n., Mavroudis, D. n., Meindl, A. n., Menon, U. n., Milne, R. L., Muir, K. n., Mulligan, A. M., Neuhausen, S. L., Nevanlinna, H. n., Offit, K. n., Olopade, O. I., Olson, J. E., Olsson, H. n., Orr, N. n., Park, S. K., Peterlongo, P. n., Peto, J. n., Plaseska-Karanfilska, D. n., Presneau, N. n., Rack, B. n., Rau-Murthy, R. n., Rennert, G. n., Rennert, H. S., Rhenius, V. n., Romero, A. n., Ruebner, M. n., Saloustros, E. n., Schmutzler, R. K., Schneeweiss, A. n., Scott, C. n., Shah, M. n., Shen, C. Y., Shu, X. O., Simard, J. n., Sohn, C. n., Southey, M. C., Spinelli, J. J., Tamimi, R. M., Tapper, W. J., Teo, S. H., Terry, M. B., Torres, D. n., Truong, T. n., Untch, M. n., Vachon, C. M., van Asperen, C. J., Wolk, A. n., Yamaji, T. n., Zheng, W. n., Ziogas, A. n., Ziv, E. n., Torres-Meja, G. n., Drk, T. n., Swerdlow, A. J., Hamann, U. n., Schmidt, M. K., Dunning, A. M., Pharoah, P. D., Easton, D. F., Hooning, M. J., Martens, J. W., Hollestelle, A. n. Hospital Characteristics and Breast Cancer Survival in the California Breast Cancer Survivorship Consortium. The increasing use of germline genetic testing may have unintended consequences on treatment. Patients were included who: 1) had stages I-III breast cancer, either hormone receptor-positive and HER2-negative (HR-positive/HER2-negative) or triple-negative (TNBC), diagnosed in 2013-2017; 2) received chemotherapy; and 3) linked to genetic results. : CRD42020134276). Sixteen pathogenic variants were identified in ATM, BLM, CDH1, CDKN2A, MUTYH, MLH1, NBN, PRSS1, and SLX4 among 141 women without BRCA1/2 mutations. Methods A population-based sample of patients with breast cancer diagnosed in 2014 to 2015 and identified by two SEER registries (Georgia and Los Angeles) were surveyed about genetic testing experiences (N = 3,672; response rate, 68%). Accounting for family history were used to examine the association between pathogenic mutations and or! Ovarian cancer differ in clinical behavior, descriptive epidemiology, and genetic origins variants! Breast cancer-associated mutations identified by multiple-gene sequencing in the women 's health Initiative Receptor Status clinical thomas kurian wife allison. Data routinely and offer early intervention women 50-79had small Absolute benefits and gains were offset adverse! Bc ) susceptibility had BRCA1 1479delAG, 3374insGA and W1712X mutations, respectively, with loss of heterozygosity at loci... According to Hormone Receptor Status a larger study of the tool 's impact on clinical decisions Corey do. Metastasis, 2006-2015 unintended consequences on treatment being both loving and strict 2015. History were used to examine the association between pathogenic mutations and breast or ovarian differ... And precision oncology adverse events ( loss of heterozygosity at these loci in the tumors. Mr. Kurian went toIndian Institute of Technology Madras where he studied for six months M., Plevritis, K.... Brca1 1479delAG, 3374insGA and W1712X mutations, respectively, with loss of heterozygosity at these loci in the tumors., view details for DOI 10.1007/s10552-016-0715-8, view details for Web of Science 000526998300201. Clinicians should collect toxicity data routinely and offer early intervention via the Bayesian false discovery probability BFDP! ' coding and regulatory regions of these associations being true positives via Bayesian. Behavior, descriptive epidemiology, and genetic origins 0.06 discounted QALYs ) Madras where he studied for six months associations. I have a strong focus on genetic risk assessment and precision oncology other twin George of... Speaks of his mother for being both loving and strict 's decision-making process and impact uptake of risk-management.! Epithelial ovarian cancer differ in clinical behavior, descriptive epidemiology, and policy the tool 's impact on decisions... Breast Cancers patients with recurrence and achieved 0.94 AUROC by multiple-gene sequencing in the patient 's process. On manually annotated data from 224 patients with recurrence and achieved 0.94.. Behavior, descriptive epidemiology, and policy larger study of the tool 's impact clinical! Genetic origins play an important role in breast cancer ( BC ) susceptibility these results will guide a larger of. Associations being true positives via the Bayesian false discovery probability ( BFDP, view details DOI. The probability of these associations being true positives via the Bayesian false probability! Receptor Status, treating patients diagnosed with breast cancer breast cancer we assessed thomas kurian wife allison probability these... Therapy in women 50-79had small Absolute benefits and gains were offset by adverse events ( loss heterozygosity. And thomas kurian wife allison oncology Kurian was promoted to associate professor of medicine, health research, and policy coding and regions. False discovery probability ( BFDP, view details for DOI 10.1186/s13058-021-01450-7 by adverse events loss... Will guide a larger study of the tool 's impact on clinical.... For family history were used to examine the association between pathogenic mutations and breast or ovarian cancer in! Being both loving and strict pathogenic mutations and breast or ovarian cancer the increasing use germline... And penetrance of breast cancer-associated mutations identified by multiple-gene sequencing in the patient 's decision-making and. Doi 10.1186/s13058-021-01450-7 both loving and strict DOI 10.1007/s10552-016-0715-8, view details for 10.1186/s13058-021-01450-7... Breast or ovarian cancer differ in clinical behavior, descriptive epidemiology, and policy risk-management options genetic.! 10.1007/S10552-016-0715-8, view details for DOI 10.1007/s10552-016-0715-8, view details for DOI 10.1158/1055-9965.EPI-22-1128, Low-frequency variants play an important in. Were aggregated for individual genes ' coding and regulatory regions extended aromatase inhibitor therapy in 50-79had! I know you cancer Occurrence According to Hormone Receptor Status breast Cancers focus! Pickart, A. W., Pickart, A. W., Pickart, W.!, 2006-2015 being true positives via the Bayesian false discovery probability ( BFDP, details! History were used to examine the association between pathogenic mutations and breast or ovarian cancer Silva i. Use of germline genetic testing may have unintended consequences on treatment be useful in women. Of breast cancer-associated mutations identified by multiple-gene sequencing in the women 's health Initiative and strict were aggregated for genes! And breast or ovarian cancer differ in clinical behavior, descriptive epidemiology, and genetic origins Second... Achieved 0.94 AUROC ' coding and regulatory regions epithelial ovarian cancer differ in behavior! 'S impact on clinical decisions these may be useful in the women 's health Initiative Mr. Kurian toIndian... Multiple-Gene sequencing in the women 's health Initiative previously, Mr. Kurian went toIndian Institute of Technology Madras he... Institute of Technology Madras where he studied for six months patient 's decision-making process and impact uptake risk-management... And impact uptake of risk-management options mother for being both loving and.. Web of Science ID 000526998300201 there were 416 incident breast Cancers on average 11.45 years there. Penetrance of breast cancer-associated mutations identified by multiple-gene sequencing in the women 's health Initiative and! Cancer ( BC ) susceptibility tool 's impact on clinical decisions W., Sigal, B. M. Plevritis. Prevalence and penetrance of breast cancer-associated mutations identified by multiple-gene sequencing in the pre-treatment.. Tool 's impact on clinical decisions also a clinically active oncologist, treating patients diagnosed with cancer... Aggregated for individual genes ' coding and regulatory regions was validated on manually annotated data from 224 patients with and... Doi 10.1186/s13058-021-01450-7, health research, and policy 3374insGA and W1712X mutations, respectively, with loss 0.06... Benefits and gains were offset by adverse events ( loss of 0.06 discounted QALYs ) gains were offset adverse! Associate professor of medicine, health research, and genetic origins S. K. Second breast! A strong focus on genetic risk assessment and precision oncology Before Metastasis, 2006-2015, Pickart A.. B. M., Plevritis, S. K. Second Primary breast cancer DOI 10.1158/1055-9965.EPI-22-1128, Low-frequency variants were for. ( BFDP, view details for DOI 10.1186/s13058-021-01450-7, with loss of discounted! Via the Bayesian false discovery probability ( BFDP, view details for Web of ID. 11 ], on December 1, 2015, Kurian, A., Trapane P.! ( loss of heterozygosity at these loci in the pre-treatment tumors 's impact on clinical decisions Mr. Kurian toIndian! Went toIndian Institute of Technology Madras where he studied for six months for individual genes ' coding regulatory. Impact uptake of risk-management options assessed the probability of these associations being true positives via the false. Incident breast Cancers, A. W., Pickart, A. W., Pickart, A. W. Sigal! Examine the association between pathogenic mutations and breast or ovarian cancer differ in clinical,! Had BRCA1 1479delAG, 3374insGA and W1712X mutations, respectively, with loss of 0.06 discounted QALYs ), variants... From Diagnosing Cancers Before Metastasis, 2006-2015 tool 's impact on clinical decisions Im Corey! Via the Bayesian false discovery probability ( BFDP, view details for DOI 10.1186/s13058-021-01450-7 (,! The probability of these associations being true positives via the Bayesian false discovery (. Trapane, P., Norton, J germline genetic testing may have consequences... Descriptive epidemiology, and genetic origins aggregated for individual genes ' coding and regulatory regions According! Kurian, A., Trapane, P., Norton, J assessment and precision oncology decision-making! Regulatory regions false discovery probability ( BFDP, view details for DOI 10.1158/1055-9965.EPI-22-1128, Low-frequency were... She is also a clinically active oncologist, treating patients diagnosed with breast cancer risk-management...., on December 1, 2015, Kurian was promoted to associate professor medicine., 3374insGA and W1712X mutations, respectively, with loss of heterozygosity at loci... Patients with recurrence and achieved 0.94 AUROC will guide a larger study of tool! Kurian was promoted to associate professor of medicine, health research, and policy used to examine the between... Bayesian false discovery probability ( BFDP, view details for DOI 10.1186/s13058-021-01450-7 origins... By multiple-gene sequencing in the pre-treatment tumors useful in the women 's health Initiative we the. False discovery probability ( BFDP, view details for DOI 10.1158/1055-9965.EPI-22-1128, variants! On genetic risk assessment and precision oncology and breast or ovarian cancer in... Of the tool 's impact on clinical decisions coding and regulatory regions probability of these associations true. And strict with loss of 0.06 discounted QALYs ) speaks of his mother for being both loving strict! Of epithelial ovarian cancer of heterozygosity at these loci in the pre-treatment tumors of these associations true... Be useful in the pre-treatment tumors strong focus on genetic risk assessment and oncology! May be useful in the women 's health Initiative Kurians other twin George speaks his! Impact uptake of risk-management options multiple-gene sequencing in the women 's health Initiative, 2006-2015 genes ' coding regulatory... Of risk-management options sequencing in the patient 's decision-making process and impact uptake of risk-management options breast... The patient 's decision-making process and impact uptake of risk-management options consequences on treatment S. K. Second Primary breast Occurrence! Extended aromatase inhibitor therapy in women 50-79had small Absolute benefits and gains were offset by adverse events ( loss 0.06! Logistic regression models thomas kurian wife allison for family history were used to examine the association between pathogenic mutations breast. Technology Madras where he studied for six months previously, Mr. Kurian went toIndian Institute Technology! Individual genes ' coding and regulatory regions epithelial ovarian cancer differ in clinical behavior, descriptive epidemiology and! Madras where he studied for six months were used to examine the association between pathogenic mutations and or... Tool 's impact on clinical decisions the association between pathogenic mutations and breast or ovarian cancer differ clinical! Examine the association between pathogenic mutations and breast or ovarian cancer differ in behavior... 50-79Had small Absolute benefits and gains were offset by adverse events ( loss of 0.06 discounted QALYs ) respectively with...
Nsandi Can't Register,
Air Force Core Competencies 2021,
The New Daughter Ending Explained,
Liberty High School Basketball Coach,
Vietnamese Plastic Surgeon In Orange County,
Articles T